CD46, Monoclonal Antibody

MCP, CD46, Trophoblast leukocyte common antigen, TLX, measles virus receptor

For Research Use Only. Not for use in diagnostic procedures.

Monoclonal

Rat IgG2a

Rat

1 ml (100 u/ml) 0.2 um filtered antibody solution in PBS, containing 0.1% bovine serum albumin and 0.02% sodium azide.

Product should be stored at 4 degree C. Under recommended storage conditions, product is stable for one year.

Small volumes of anti-CD46 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Product Description: The monoclonal antibody MM10 recognizes membrane cofactor protein (MCP), also known as CD46. MCP is a type I membrane glycoprotein that consists of four isoforms i.e. two C-isoforms (51-58 kDa) and two BC isoforms (59-68 kDa) which arise by alternative splicing of a single CD46 gene. Membrane cofactor protein is expressed on every cell and tissue, with the exception of erythrocytes. Membrane cofactor protein serves to down-regulate the activation of complement on host tissue. MCP is a cofactor for factor 1-mediated cleavage of C3b and C4b and this way serves to protect the host cell against autologous attack. MCP is a receptor for several pathogens including measles virus, group A Streptococcus pyogenes and pathogenic Neisseria.

F, Flow Cytometry (FC/FACS), Immunoassay (IA), Immunofluorescence (IF), Western Blot (WB)

Application Use: For immune histology, flow cytometry and western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilution. The typical starting working dilution is 1:50.

36,826 Da

CD46 molecule, complement regulatory protein

membrane cofactor protein; measles virus receptor; complement membrane cofactor protein; trophoblast leucocyte common antigen; trophoblast leukocyte common antigen; CD46 antigen, complement regulatory protein; trophoblast-lymphocyte cross-reactive antigen; antigen identified by monoclonal antibody TRA-2-10; membrane cofactor protein (CD46, trophoblast-lymphocyte cross-reactive antigen)

Membrane cofactor protein

MCP; MIC10  [Similar Products]

MCP_HUMAN

The protein encoded by this gene is a type I membrane protein and is a regulatory part of the complement system. The encoded protein has cofactor activity for inactivation of complement components C3b and C4b by serum factor I, which protects the host cell from damage by complement. In addition, the encoded protein can act as a receptor for the Edmonston strain of measles virus, human herpesvirus-6, and type IV pili of pathogenic Neisseria. Finally, the protein encoded by this gene may be involved in the fusion of the spermatozoa with the oocyte during fertilization. Mutations at this locus have been associated with susceptibility to hemolytic uremic syndrome. Alternatively spliced transcript variants encoding different isoforms have been described. [provided by RefSeq, Jun 2010]

CD46: Acts as a cofactor for complement factor I, a serine protease which protects autologous cells against complement- mediated injury by cleaving C3b and C4b deposited on host tissue. May be involved in the fusion of the spermatozoa with the oocyte during fertilization. Also acts as a costimulatory factor for T- cells which induces the differentiation of CD4+ into T-regulatory 1 cells. T-regulatory 1 cells suppress immune responses by secreting interleukin-10, and therefore are thought to prevent autoimmunity. A number of viral and bacterial pathogens seem to exploit this property and directly induce an immunosuppressive phenotype in T-cells by binding to CD46. Defects in CD46 are a cause of susceptibility to hemolytic uremic syndrome atypical type 2 (AHUS2). An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype. Patients with CD46 mutations seem to have an overall better prognosis compared to patients carrying CFH mutations. 16 isoforms of the human protein are produced by alternative splicing.

Protein type: Receptor, misc.; Cell surface; Membrane protein, integral

Chromosomal Location of Human Ortholog: 1q32

Cellular Component: Golgi apparatus; inner acrosomal membrane; focal adhesion; cell surface; integral to plasma membrane; basolateral plasma membrane; plasma membrane

Molecular Function: enzyme inhibitor activity; complement binding; protein binding; cadherin binding; endopeptidase activity; receptor activity

Biological Process: positive regulation of memory T cell differentiation; adaptive immune response; positive regulation of regulatory T cell differentiation; viral reproduction; T cell mediated immunity; proteolysis; positive regulation of interleukin-10 production; regulation of Notch signaling pathway; negative regulation of complement activation; single fertilization; negative regulation of catalytic activity; interleukin-10 production; regulation of complement activation; innate immune response; positive regulation of T cell proliferation; complement activation, classical pathway

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.